• Early molecular response in CML matters

    EARLY MOLECULAR RESPONSE MATTERS

    ≤10% BCR-ABL at 3 months may impact OS1

    Early molecular response in CML matters

    In a retrospective trial, BCR-ABL transcript levels were analyzed in 282 patients with chronic phase CML who were monitored at 3, 6, and 12 months to identify molecular milestones that predicted for OS and other outcomes.1

  • Early molecular response in CML matters

    ROUTINE TESTING TELLS YOU MORE

    Routine CML testing tells you more

    The hazard of disease progression was 91% lower for patients in the group that received 3 to 4 RQ-PCR tests per year compared with the group that received 0 RQ-PCR tests per year.2

  • Early molecular response in CML matters

    STANDARDIZED BASELINE MEANS COMPARABLE RESULTS

    International Scale for RQ-PCR testing
    Early molecular response in CML matters

*Limitations Apply. Non-US residents, patients covered under Medicare, Medicaid, or a similar state or federal program, and residents of Massachusetts and Michigan are not eligible for the Get IS RQ-PCR Now program.

OS, overall survival; IS, International Scale; CML, chronic myeloid leukemia; RQ-PCR, real-time quantitative polymerase chain reaction.

References: 1. Marin D, Ibrahim AR, Lucas C, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30(3):232-238. 2. Goldberg SL, Chen L, Guerin A, et al. Curr Med Res Opin. 2013;29(9):1075-1082.

IS, International Scale; RQ-PCR, real-time quantitative polymerase chain reaction.